| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.24 | 1-year : | 10.51 |
| Resists | First : | 7.91 | Second : | 9 |
| Pivot price | 7.17  |
|||
| Supports | First : | 6.15 | Second : | 5.12 |
| MAs | MA(5) : | 6.71 |
MA(20) : | 7.48 |
| MA(100) : | 7.19 |
MA(250) : | 8.92 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 12.9 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 26.6 | Low : | 0.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PASG ] has closed below upper band by 39.0%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.96 - 7 | 7 - 7.03 |
| Low: | 6.23 - 6.28 | 6.28 - 6.32 |
| Close: | 6.63 - 6.71 | 6.71 - 6.77 |
Tue, 11 Nov 2025
How to read the order book for PASG - July 2025 Sector Moves & Low Volatility Stock Recommendations - newser.com
Mon, 10 Nov 2025
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
Mon, 10 Nov 2025
Passage Bio Reports Q3 Financial Results and Updates - TipRanks
Mon, 10 Nov 2025
Passage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDA - Quiver Quantitative
Mon, 10 Nov 2025
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
Mon, 10 Nov 2025
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 55.4 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 82 (K) |
| EPS | 39.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -88.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -16.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | 0.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|